Blowin' Smoke

Tuesday May 1, 2012
	Refer a Friend  |  Visit Our Website  |  Unsubscribe   Advertisers
		Blowin' Smoke   by Rob Goldman   Here we are again, writing up a sin stock.  In this case, I am not really sure what to make of this company.  On the one hand, it seems pretty cool. On the other hand, the business model seems, well, tough.    The stock has had a big run in 2012 and consistently trades more than one million shares per day, so liquidity and broad interest is definitely there, which caught our attention.  There are a lot of people smarter than me out there so I tend to give these guys the benefit of the doubt, though by a slim margin.    Star Scientific, Inc. (NASDAQ - CIGX - $3.62) develops and licenses tobacco-curing technology that prevents the formation of traditional carcinogenic toxins in tobacco and tobacco smoke.  The company's guiding principles are based on the basic tenet that it is technologically possible to reduce the health risks associated with long-term tobacco use.  Thus, much of CIGX's R&D efforts are focused on developing methods that result in the manufacture of tobacco products that contain as few toxins as possible.   To read more click here >> or visit http://www.pennystockjunction.com   Three Ways to Make Money   by Rob Goldman   When you buy a stock, you usually have only that one opportunity to make money.   Wouldn't it be great if you can substantially increase those odds? You may be able to do just that by buying Neptune Technologies and Bioressources Inc. (NASDAQ: NEPT - $3.45).    Through three operating segments/subsidiaries, NEPT develops and commercializes novel marine bioactive ingredients, specifically omega-3 phospholipids from underexploited marine biomass such as cold, deep water krill found in Antarctica.  Neptune develops and markets offerings for the nutraceutical market treatment, and product development for cardiovascular diseases (Acasti Pharma subsidiary) and neurological diseases (NeuroBioPharm subsidiary).   The key takeaways for investors are threefold.  First, the Neptune business is doing extremely well and shareholders will benefit greatly from sales growth this year.  Second, Neptune owns 57% of Acasti Pharma Inc. (APO: TSXV - $2.25), which is publicly traded in Canada.  Therefore, investors get to participate in the development of this business as well.   To read more click here >> or visit http://www.pennystockjunction.com

		Disclaimer & Important Information PennyStockJunction.com is owned and published by Champlain Media, LLC of Richmond, Vermont. Champlain Media is neither a registered investment adviser nor a broker/dealer. Readers are advised that this electronic publication is issued solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. We encourage you to review our full Disclaimer and Disclosure policies. To view our Disclaimer Policy, please click here. To view our Disclosure Policy, please click here. You are subscribed with the following email address: ignoble.experiment@arconati.us To unsubscribe from this newsletter, please click here. Interested in advertising with us? CLICK HERE!   Copyright (c) 2012 Penny Stock Junction | Privacy Policy c/o Champlain Media 65 Railroad Street Richmond, VT 05477 PO Box 790